IFN-alpha-stimulated genes and Epstein-Barr virus gene expression distinguish WHO type II and III nasopharyngeal carcinomas

Pegtel DM, Subramanian A, Meritt D, Tsai CH, Sheen TS, Golub TR, Thorley-Lawson DA. IFN-alpha-stimulated genes and Epstein-Barr virus gene expression distinguish WHO type II and III nasopharyngeal carcinomas. Cancer Res. 2007;67:474–81.

NOTES

Pegtel, D MichielSubramanian, AravindMeritt, DavidTsai, Ching-HwaSheen, Tzung-ShiahnGolub, Todd RThorley-Lawson, David AengAI 18757/AI/NIAID NIH HHS/CA 65883/CA/NCI NIH HHS/Research Support, N.I.H., ExtramuralCancer Res. 2007 Jan 15;67(2):474-81. doi: 10.1158/0008-5472.CAN-06-1882.

Abstract

Nonkeratinizing nasopharyngeal carcinoma (NPC) is 100% associated with Epstein-Barr Virus (EBV) and divided into two subtypes (WHO types II and III) based on histology. We tested whether these subtypes can be distinguished at the molecular genetic level using an algorithm that analyzes sets of related genes (gene set enrichment analysis). We found that a class of IFN-stimulated genes (ISG), frequently associated with the antiviral response, was significantly activated in type III versus type II NPC. Consistent with this, replication of the endogenous EBV was suppressed in type III. A strong association was also seen with a subset of ISGs previously identified in systemic lupus erythematosus, another disease in which 'normal' EBV biology is deregulated, suggesting that this pattern of ISG expression may be linked to the increased EBV activity in both diseases. In contrast, unsupervised hierarchical clustering of the complete expression profiles failed to distinguish the two subsets. These results suggest that type II and III NPC have not originated from obviously distinct epithelial precursors; rather, the histologic differences may be a consequence of a differential antiviral response, involving IFNs, to chronic EBV infection.
Last updated on 02/17/2021